华特达因(000915) - 2025 Q3 - 季度财报

Financial Performance - For the first nine months of 2025, the company achieved operating revenue of CNY 1.603 billion, with a net profit attributable to shareholders of CNY 408 million, representing year-on-year growth of 16.30% and 11.67% respectively[4] - The pharmaceutical business generated operating revenue of CNY 1.578 billion and a net profit of CNY 757 million, reflecting increases of 16.77% and 9.64% compared to the same period in 2024[4] - In Q3 2025, the company reported operating revenue of CNY 432 million, a significant increase of 93.28% year-on-year, and a net profit of CNY 70.6 million, up 110.42% from the previous year[5] - The basic earnings per share for the first nine months of 2025 was CNY 1.7414, marking an increase of 11.67% compared to the same period last year[5] - Net profit for the period was ¥767,418,437.12, representing a 10.8% increase from ¥692,591,722.84 in the previous period[16] - Earnings per share (EPS) for the period was ¥1.7414, compared to ¥1.5594 in the prior period, reflecting a growth of 11.6%[16] Assets and Liabilities - The company's total assets as of September 30, 2025, were CNY 4.780 billion, a decrease of 3.06% from the end of the previous year[5] - The company's total current assets amount to ¥3,372,578,876.81, a decrease from ¥3,510,737,250.04 at the beginning of the period[12] - The total assets of the company are ¥4,779,984,839.06, down from ¥4,930,936,591.73[13] - The company's total liabilities amount to ¥473,747,067.84, an increase from ¥418,011,480.27[13] - Total liabilities increased to ¥573,205,007.48 from ¥518,499,753.28, indicating a rise of 10.6%[14] - The company's equity attributable to shareholders decreased by 2.08% to CNY 2.851 billion compared to the end of the previous year[5] - Total equity attributable to shareholders decreased to ¥2,851,053,959.18 from ¥2,911,651,440.88, a decline of 2.1%[14] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 955 million, representing a 70.50% increase year-on-year[5] - The net cash flow from operating activities was CNY 954,987,097.75, an increase of 70.4% compared to CNY 560,093,957.28 in the previous period[18] - Total cash inflow from operating activities amounted to CNY 2,654,451,852.64, up from CNY 2,015,317,935.16, reflecting a growth of 31.6%[18] - Cash outflow from operating activities was CNY 1,699,464,754.89, compared to CNY 1,455,223,977.88, representing an increase of 16.8%[18] - The ending balance of cash and cash equivalents was CNY 1,820,357,317.28, an increase from CNY 1,610,259,774.32[18] Expenses - Sales expenses for the first nine months of 2025 amounted to CNY 342.8 million, a rise of 37.13% compared to the same period in 2024, attributed to higher marketing activity costs and sales personnel bonuses[9] - The company experienced a 2118.27% increase in credit impairment losses, amounting to CNY 6.6 million, mainly due to the recovery of large overdue accounts[9] - Research and development expenses were ¥68,738,075.33, slightly up from ¥64,281,936.19 in the prior period[15] - The company recorded a tax expense of ¥131,540,958.88, which is marginally higher than ¥129,753,178.59 in the previous period[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,598[10] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of shares, totaling 51,544,340 shares[10] - The company has no preferred shareholders as indicated in the report[12] Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 262.65% to CNY 203.7 million, primarily due to increased advance payments from customers[8] - The company reported a financial asset fair value change gain of ¥8,168,115.06, compared to ¥6,090,195.26 in the previous period[16] - Cash inflow from investment activities totaled CNY 2,012,895,539.01, down from CNY 2,186,690,952.50, indicating a decrease of 7.9%[18] - Cash outflow from investment activities increased to CNY 2,234,199,712.60 from CNY 2,081,136,231.58, marking a rise of 7.4%[18] - Cash flow from financing activities resulted in a net outflow of CNY -973,075,444.00, compared to CNY -1,090,241,186.50 previously[18]